Correlation Between Circulating Fibroblast Activation Protein (FAP) and Fibrosis in Two Diseases (Rheumatoid Arthritis and Systemic Sclerosis)
Starting soon
Conditions studied: Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)
In brief
This study aims to measure a blood protein called fibroblast activation protein (FAP), which is linked to tissue scarring and inflammation. A small blood sample will be taken from participants (RA , SSc patients and healthy people ), and the FAP level will be measured and compared with routine clinical examinations, imaging studies, and lung function tests. The purpose of this study is to improve understanding of disease activity and lung involvement in these conditions and to explore whether FAP could be useful as a blood marker for future patients. Participation in this study will not change the participant's usual medical care.
Key facts
- Study ID
- NCT07393217
- Run by
- Sohag University
- People needed
- 111
- Starts
- 2026-03-01
- Expected to finish
- 2027-09-01
- Last updated by the study team
- 2026-02-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Age ≥18 years. Confirmed diagnosis of RA (ACR/EULAR) or SSc (ACR/EULAR).
- Ability and willingness to provide informed consent. Cooperative patient able to answer questions.
You may not qualify if…
- Patients under 18 years' old
- Active cancer or history of cancer within 5 years.
- Other major fibrotic systemic disease that could confound circulating FAP levels.
- Acute infection at time of sampling.
- Pregnancy or breastfeeding.
- Other autoimmune diseases
Where it is running
- Sohag University Hospital — Sohag, Egypt
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.